#Finished Formulations
Explore articles tagged with Finished Formulations
Licensed in Germany, Ready for Europe
HRV Pharma's acquisition of Germany-based Phatebo GmbH provides an established entry into the European pharmaceutical market. With German pharmaceutical wholesale authorisation, good distribution practice systems and an existing global customer base, the acquisition supports HRV's expansion into finished formulations while strengthening its international presence.
Keeping Clinical Trials on Schedule
HRV Pharma's acquisition of Germany-based Phatebo expands its business into clinical trial supply and finished formulations. Phatebo provides investigational, comparator and ancillary medicines through licensed channels, with traceability of origin, batch and expiry to support reliable clinical trial operations.
A New Chapter in Europe
HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.
Into Clinical Trial Supply
HRV Pharma has expanded beyond APIs into clinical trial supply through its acquisition of Germany-based Phatebo. The company sources comparator, investigational and ancillary medicines for pharmaceutical companies and CROs worldwide, bringing HRV into a segment where reliability, traceability and timely delivery are essential.
A Foray Into European Markets
HRV Pharma is expanding into European markets through the planned acquisition of Germany-based Phatebo GmbH. The deal provides an entry into finished formulations, clinical trial supply and established pharmaceutical distribution capabilities, including a German wholesale authorisation and long-standing relationships with clinical trial sponsors.
Beyond APIs, Into Finished Formulations
HRV Pharma is expanding beyond APIs into finished formulations through its acquisition of a 100% equity stake in Germany-based Phatebo. The acquisition marks a significant step in HRV's growth, giving the company its first finished formulations business and a licensed operating presence in Germany, while opening new opportunities in the European pharmaceutical market.